Trials / Recruiting
RecruitingNCT06698003
A Study of Mogamulizumab to Prevent Adult T-cell Leukemia/Lymphoma in People With HTLV-1
A Phase 2 Study for Screening and Prevention of Adult T-cell Leukemia/Lymphoma With Mogamulizumab in High-Risk Carriers of HTLV-1
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 134 (estimated)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to find out whether the study drug mogamulizumab is effective in preventing the development of adult T-cell leukemia/lymphoma (ATL) in people who are at higher risk for this type of cancer because they are infected with the HTLV-1 virus and because of changes seen in some of their immune system cells called T-cells.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Mogamulizumab | Cohort 1: 0.3 mg/kg of mogamulizumab every 12 weeks, for 2 total doses Cohort 2: 0.3 mg/kg of mogamulizumab every 6 weeks, for 4 total doses |
Timeline
- Start date
- 2024-11-15
- Primary completion
- 2029-11-15
- Completion
- 2029-11-15
- First posted
- 2024-11-20
- Last updated
- 2026-03-05
Locations
7 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06698003. Inclusion in this directory is not an endorsement.